Purpose

In this study, xenon MRI will be used to evaluate regional functional consequences of mucus plugs in the lungs of patients with severe asthma. Mucus plugs will be identified using CT imaging, and xenon MRI will be used to evaluate ventilation and gas exchange impairments in regions of the lungs corresponding to the airways downstream of mucus plugs.

Condition

Eligibility

Eligible Ages
Between 18 Years and 65 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adequate completion of informed consent process with written documentation - Patients 18 - 65 years old - Physician diagnosis of asthma for > 1 year - Able to perform reproducible spirometry according to ATS criteria based on clinical PFTs. - Blood eosinophil count > 300 cells/μL and FeNO >25ppb - Smoking history <10 pack years - No smoking history (including vapes, cigar, or marijuana use) in the last 3 months - Approved for asthma therapy with either dupilumab, tezepelumab, or benralizumab as part of their standard of care

Exclusion Criteria

  • Respiratory tract infection within the 4 weeks prior to Visit 1 - Body mass index (BMI) > 30 at Visit 1 - One-time doses such as intra-articular injections require a 4-week washout prior to Visit 1 - Asthma-related ER visit within the previous 4 weeks of Visit 1 - Significant concomitant medical illness, including (but not limited to) heart disease, cancer, uncontrolled diabetes, other chronic lung diseases (determined by the Investigator.) - Resting O2 saturation <90% with maximum supplemental O2 delivered by nasal canula - Positive urine pregnancy test at Visit 1 or at any time while on the study - Participation in an intervention study (including bronchoscopy) or use of investigative drugs within the past 30 days or plans to enroll in such a trial during the study - Unable or unlikely to complete study assessments in the opinion of the Investigator - Study intervention poses undue risk to patient in the opinion of the Investigator - Conditions that will prohibit MRI scanning determined by the MRI safety screening.

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Main Group Patients with Severe Asthma with a high T2 phenotype
  • Combination Product: Hyperpolarized 129 Xenon
    Xenon gas contrast agent for MRI

Recruiting Locations

University of Kansas Medical Center
Kansas City, Kansas 66160
Contact:
Cristal Monge
913-945-9399
chernandez@kumc.edu

More Details

Status
Recruiting
Sponsor
University of Kansas Medical Center

Study Contact

Cristal Monge
(913) 945-9399
chernandez@kumc.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.